ATXI - Avenue Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Avenue Therapeutics, Inc.

2 Gansevoort Street
9th Floor
New York, NY 10014
United States
781-652-4500
http://www.avenuetx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. Lindsay Allan RosenwaldExec. ChairmanN/AN/A1955
Dr. Lucy LuPres, CEO & Director639.78kN/A1975
Mr. Joseph Walter VazzanoCFO, Principal Financial Officer & Company Sec.258.78kN/A1984
Dr. Scott A. ReinesInterim Chief Medical OfficerN/AN/A1947
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.

Corporate Governance

Avenue Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.